Organic Active Ingredients TRIZ Cases

Formula I substituted amides modulate the farnesoid X receptor, resolving stability versus toxicity trade-offs to improve therapeutic efficacy.

Linking Resiquimod to an anti-HER2 antibody overcomes tumor resistance by activating macrophages and dendritic cells to produce TNFα.

Adding polyethylene glycol to indomethacin formulations prevents low-temperature crystal precipitation while maintaining high percutaneous absorption.

Inhibiting specific transcription factors with nucleic acid agents restores damaged cardiac tissue by increasing cardiomyocyte division rates.

Nitrogen atmosphere processing prevents oxidation during polymer synthesis, eliminating leachable tin by-products in radiolabeled MIBG preparations.

Pyrimidinone compounds inhibit Lp-PLA2, reducing lysophosphatidylcholine production to treat atherosclerosis and Alzheimer's disease.

Amphiphilic polymer nanoaggregates solubilize poorly water soluble bioactive agents, eliminating complex surfactant systems and reducing manufacturing costs.

Targeting conserved 5'-UTR regions enables broad-spectrum efficacy against diverse rhinovirus strains, overcoming serotype variability.

Hsp70 stabilizes lysosomal membranes to enable broad-spectrum enzyme uptake, addressing high costs of specific replacements.

Segmented tetrahydropyran thiodisaccharides inhibit Galectin-3 to treat fibrotic diseases lacking effective inhibitors.

Combining anti-CD38 antibodies with survivin inhibitors targets hematological malignancies through enhanced cytotoxicity.

Flexible hydrogel matrix on expandable devices retains microparticulates during insertion, then releases them at the target site to prevent premature loss.

Multi-particle oral dosage form combines immediate and pH-sensitive delayed release particles to extend therapeutic phenylephrine levels beyond four hours.

Nootkatone treats depression with 95% clinical effectiveness, eliminating toxicity and side effects found in conventional antidepressants.

A nasal spray composition uses niacin-related compounds to induce vasodilation and reduce congestion.

Saracatinib targets Fyn kinase to interrupt Aβ-mediated neurotoxicity, addressing the failure of direct amyloid therapies to modify disease progression.

Deazapurine compounds inhibit Janus kinases by removing nitrogen from the purine ring to resolve limited inhibitor availability.

Specific primers and probes isolate EML4-ALK fusion sequences to resolve low detection precision, enabling targeted inhibitor screening for lung cancer therapy.

Modified SERM structures overcome tamoxifen resistance and reduce side effects by targeting PKCα-positive tumors without inducing uterine weight gain.

Substituted indole compounds inhibit Toll-like receptor 7, 8, and 9 signaling to reduce cytokine production in inflammatory diseases.

Nanoparticles carrying micheliolide derivatives sensitize cancer cells to ionizing radiation and immune checkpoint inhibitors.

Segmented Mpro inhibitors resolve the contradiction between treatment effectiveness and compound availability by optimizing residue positions.

siRNAs degrade DUX4 mRNA to lower toxic protein levels, addressing ineffective FSHD treatments.

Dynamic telmisartan dosing lowers urinary protein-to-creatinine ratio in dogs refractory to ACE inhibitors.

Segmenting the drug into a linear and circular strand protects the complex from nuclease degradation while reducing off-target effects.

Exosomes from cytotoxic T cells kill mesenchymal cells to suppress tumor proliferation and metastasis.

Specific microRNAs in blood samples diagnose osteoporosis, resolving low accuracy of bone density measurements in diabetic patients.

Selective CB2 receptor ligands modulate gene expression to restore vaginal tissue health without hormone replacement risks.

Inhibitors bind P-glycoprotein nucleotide domains to block efflux, restoring chemotherapy efficacy in resistant tumors.

Benzaldehyde mediated photo redox reaction creates selective beta-catenin BCL9 inhibitors.

A composition of ligustroflavone, rhoifolin, and hyperin inhibits influenza virus neuraminidase activity.

Optimized methyl salicylate content and 30000 to 75000 Pa modulus balance drug release with adhesion stability on moving joints.

A gelatinized HPMC hard capsule formulation controls 25-hydroxyvitamin D release using a cellulose ether and gellan gum matrix.

Specific Lactobacillus helveticus strains maintain immunomodulatory activity within complex nutritional matrices, reducing allergic symptoms.

Defined synthetic lipid species compositions enable standardized anti-phosphatidylethanolamine antibody detection in immunoassays.

A sustained-release tablet uses a composite gel matrix to trap active ingredients and deter injection misuse.

Palladium-catalyzed Suzuki coupling synthesizes the arylomycin ring, resolving low yield and racemization issues in antibiotic analog manufacturing.

Extracellular SLC26A3 inhibitors reduce oxalate absorption while minimizing systemic availability to treat constipation and kidney stones.

Segmented application protocols optimize biological interplay by sequencing cleansing actives before repair agents to maximize anti-aging benefits.

Non-aqueous vehicles prevent nucleophilic decomposition of mechlorethamine hydrochloride, reducing skin hypersensitivity while maintaining therapeutic potency.

Positive allosteric modulators bind distinct sites to boost endogenous ligand effects, avoiding rapid desensitization and sustaining therapeutic efficacy.

Overexpressing miR-200 family members reverses epithelial-to-mesenchymal transition, restoring sensitivity to cytotoxic therapies and reducing metastasis.

Modified nandrolone derivatives lacking C4-C5 double bonds enhance sexual desire through androgen receptor modulation.

A stable crystal form of a hepatitis B surface antigen inhibitor enhances drug bioavailability and stability.

Replacing citric acid with amino acids inhibits 7-epi-docetaxel formation, maintaining chemical stability for extended periods.

Imidazoquinoline derivatives activate toll-like receptors 7 and 8, resolving the lack of effective agonists for treating viral infections and cancers.

Analyzing miR-3151 and BAALC expression levels identifies acute myeloid leukemia patients with poor prognostic outcomes.

Polyketal particles deliver CpG oligodeoxynucleotides to pulmonary tumor nodules, activating Th1 responses and reducing immunosuppressive cells.

Antibody-conjugated nanoparticles deliver cytotoxins to AMHRII-expressing gonad cells, eliminating surgical anesthesia requirements.

Replacing labile P-O bonds with stable C-C linkages in phosphonate prodrugs improves serum stability while maintaining potent Vγ9/Vδ2 T-cell activation.

Combining EGFR tyrosine kinase inhibitors with AKT inhibitors re-sensitizes non-small cell lung cancer cells to treatment by delaying resistance onset.

Modified 6-hydroxy-cannabidiol-C4 structure overcomes treatment resistance in pediatric epilepsy, reducing neurological damage.

Specific nucleotide modifications at the 5' end increase affinity for Argonaute 2, resolving insufficient knockdown activity in RNA interference applications.

NEK7 inhibitors with specific hinge-binding and hydrophobic features modulate the NLRP3 inflammasome for therapeutic use.

Soluble FZD-Fc fusion proteins intercept Wnt ligands, resolving the trade-off between targeted efficacy and treatment complexity in cancer therapy.

A solid dispersion using gamma-cyclodextrin inclusion complexes overcomes poor dutasteride solubility, reducing dosage bulk while improving stability.

Asperuloside directly binds Nrf2 to suppress oxidative stress, resolving vascular impairment without traditional side effects.

Pax6 inhibitors reduce Tau phosphorylation and amyloid beta plaques, preventing neuronal cell death and improving learning and memory.

Identifying POTS patients with elevated CRTH2 expression enables targeted CRTH2 antagonist therapy, addressing the lack of FDA-approved treatments.

A pharmaceutical formulation of (S)-pindolol combines beta-adrenergic antagonism with 5-HT1a partial agonism to address cachectic weight loss.

A stackable routing clip with a weld projection secures cables to machinery via a single automated weld operation.

Compounds targeting B-Raf V600E mutations improve therapeutic effectiveness for melanoma and colorectal cancer patients.

Bicyclic nucleoside modifications enhance miR-21 binding potency while maintaining synthesis feasibility.

A gelled oil-in-water emulsion disperses veterinary drugs in a flavored water phase to enhance palatability and bioavailability.

Modifying the naphthyridine scaffold parameters optimizes binding affinity to enhance biological activity while avoiding cardiovascular damage risks.

Sterile nebulizer composition combines chlorpheniramine maleate with albuterol to reduce viral loads by over 80% while providing bronchodilation.

Sulfobutyl ether-beta-cyclodextrin inclusion complexes resolve the trade-off between anethole trithione solubility and chemical stability.

Cpf1 endonuclease and guide RNA target the dystrophin gene to delete exons, restoring the reading frame without repeated administration.

Combining a KRAS G12C inhibitor with MAPK or PI3K pathway agents overcomes resistance mechanisms and improves treatment efficacy.

BAM15 transfers protons across the mitochondrial inner membrane to stimulate respiration and improve insulin sensitivity.

Combining BDNF or TrkB agonists with beta blockers prevents catecholamine toxicity while improving cardiac force generation.

Administering an anti-C1q antibody inhibits the classical complement pathway, preventing memory decline and synapse loss after traumatic brain injury.

A pharmaceutical composition combining serine, N-acetyl cysteine, carnitine, and nicotinamide riboside to lower serum uric acid levels.

A freeze-dried chitosan polymer matrix retains bioactive plasma components to prevent rapid drainage and extend contact time on the ocular surface.

Levocarnitine addresses OCTN2 transport defects to alleviate dry eye and arthritis while slowing disease progression.

Extracellular polysaccharide from Ceriporia lacerata inhibits phosphodiesterase-5 activity, offering erectile dysfunction treatment with minimal toxicity.

Liposomes encapsulating polymer nanoparticles maintain physical stability in aqueous solutions, enabling sustained drug release without rapid degradation.

Aryl lactam compounds inhibit adaptor associated kinase 1 to treat schizophrenia and Alzheimer's disease.

Pyrazolopyridine derivatives inhibit protein kinase C theta to treat inflammatory disorders while managing drug development complexity.

Novel pentacyclic triterpenoids antagonize FXR receptors through structural inversion at position 3 and specific amino acid substitution at position 17.

Formula I compounds enhance interferon production to overcome limited therapeutic potential in cancer treatment.

A transdermal patch uses a composite adhesive matrix to deliver active agents through the skin.

Isothiocyanate-AR inhibitor conjugates overcome resistance to existing AR inhibitors by inducing ferroptosis in prostate cancer cells.

Segmented synthesis of netarsudil uses preliminary nitrogen protection to resolve yield scalability contradictions, enabling large-scale production.

A sequential regimen combining doxorubicin with a DNA-PK inhibitor blocks repair mechanisms to overcome single-agent limitations.

Subcutaneous RAGE RNAi agents with 2'-O-methyl modifications resolve potency and specificity bottlenecks by targeting pulmonary epithelial cells.

Humanized anti-ROR1 antibodies minimize immunogenicity while maintaining high binding affinity to effectively kill cancer cells.

A fused ring pyrimidine compound inhibits JAK, FGFR, FLT3, and Src family kinases through a single molecular structure.

Bicyclic heterocyclic derivatives selectively inhibit PDHK enzymes to reduce undesired cell populations in cancer and diabetes treatments.

Weak organic acids buffer livestock footbath solutions to prevent metal salt precipitation caused by alkaline waste.

Adenosine sulfamate analogs inhibit ATG7 enzyme activity through covalent adduct formation, resolving the lack of effective inhibitors for cancer treatment.

A lipid-based topical injection formulation uses ionizable lipids to bind mRNA and increase local bioavailability.

Pyrimidine compounds inhibit EGFR and ERBB2 exon 20 insertion mutations, resolving low response rates in non-small cell lung cancer.

Reversible macrocyclic compounds inhibit wild-type and mutant BTK forms, overcoming drug resistance from catalytic site mutations.

Structural modifications reduce plasma protein binding to improve bioavailability and therapeutic index against chronic lymphocytic leukemia.